Ex-Sebelius aide purges FDA office

Share this article:
FDA associate commissioner for external affairs Beth Martino, a former Kansas aide to HHS secretary Kathleen Sebelius, has conducted an unprecedented purge of senior specialists, all aged over 50, in her office and in the Press Office which she controls.
Sources confidential to me said the abrupt removals were made to make room for younger people closer to Martino's own age. “She's uncomfortable with people who know more than she does,” some of them said. Others alleged that the moves represent deeper politicization of the agency.
Three of the displaced staffers, Elaine Gansz Bobo, Dick Thompson,  and Ira Allen were offered the choice of being terminated as probationary hires for fabricated “incompetence” or resigning. Each had been told on their recruitment that, short of criminal behavior, “everybody survives the probationary period.”
As youth seems to trump experience in the Obama administration, similar purges are reportedly occurring at other HHS agencies, including CDC.
Martino told Bobo and Allen to immediately clean out their desks and they were then escorted off the premises. Thompson, a former TIME magazine Washington bureau science editor and high-level W.H.O. communications advisor, was told to find other work outside of FDA, but was allowed to stay until his 12-month probation expired on December 2.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.